Department of Health and Social Care (DHSC) has issued a medicine supply notification for Buprenorphine/naloxone (Suboxone®) 2mg/500microgram and 8mg/2mg sublingual tablets.
MSN/2026/002
Tier 2 – Medium impact
Date of issue: 15 January 2026
- Buprenorphine/naloxone (Suboxone®) 2mg/500microgram and 8mg/2mg sublingual tablets were discontinued on 5th January 2026.
- Various strengths (0.7mg/0.18mg, 1.4mg/0.36mg, 5.7mg/1.4mg, 8.6mg/2.1mg, and 11.4mg/2.9mg) of short-dated buprenorphine/naloxone (Zubsolv®) sublingual tablets are available but future supply to the UK is to be confirmed.
- Branded and generic buprenorphine sublingual tablets (2mg and 8mg) and buprenorphine oral lyophilisate 2mg and 8mg (Espranor®) remain available.
A copy of this medicine supply notification, including supporting information, has been sent to all pharmacy NHS email addresses.
Pharmacy teams should note that Subutex® has also been discontinued and further information can be found here.
DHSC and NHS England have launched an online Medicines Supply Tool, which provides up-to-date information about medicine supply issues. The contents of these MSNs can now be viewed on the Tool.
The Tool also details any changes to resupply dates and updates to the entries.
To access the Tool you will need an NHS email address. Once set up and logged in, you will be able to access it online.
New shortages not listed on the SPS website, can be reported using our shortage reporting tool.
The post Medicine Supply Notification: Buprenorphine/naloxone (Suboxone® ) 2mg/500microgram and 8mg/2mg sublingual tablets appeared first on Community Pharmacy England.